IPROVE CONSORTIUM THIRD HIGH-LEVEL CONSULTATION MEETING ON RESEARCH & INNOVATION GAPS IN VACCINE RESEARCH TO CONVENE IN BRUSSELS ON 12-13 MARCH 2015

2015 03 12 Written by Vaccines Europe

Vaccines Europe (VE), The European Vaccine Initiative (EVI), The Sclavo Vaccines Association (SVA) and EATRIS due to meet in Brussels for penultimate workshop ahead of the final project summit with top stakeholders in the vaccine field.

Key opinion leaders in the field of vaccine research and development are meeting in the upcoming IPROVE consultation workshop in Brussels on 12 and 13 March 2015. The objective of the workshop is to formulate a consensus on future vaccine R&I activities and identify key gaps and needs to be addressed over the coming years to bolster vaccine innovation and connect across Europe the appropriate expertise needed to meet the challenge of current medical needs.

Led by representatives from each of the IPROVE partners – Vaccines Europe (VE), the European Vaccine Initiative (EVI), the Sclavo Vaccines Association (SVA), and EATRIS (the European Infrastructure for Translational Medicine), – over 50 distinguished scientists from leading academic and public health institutions, regulatory bodies, research and programming bodies, industry, and policy-makers will discuss key challenges in vaccine research proposing recommendations for targeted areas where EU support through funding and programming measures will be key over the coming years to fully leverage vaccine potential as a public health tool and source of economic growth. The workshop will also feature participation from representatives of the European Commission, the World Health Organisation, as well as the Innovative Medicines Initiative (IMI), the largest EU-based public-private partnership between the life science industry and the European Commission.

The consultation workshop expects to cover:

  • Antigen selection and vaccine design
  • Novel technologies and routes of immunisation
  • Vaccine manufacturing and quality control
  • Accelerating and simplifying data interpretation from clinical studies
  • Research infrastructures

Representatives from the World Health Organisation, Sanofi Pasteur, GlaxoSmithKline Vaccines, Novartis Vaccines, the Danish Statens Serum Institute, the Università della Svizzera Italiana, Imperial College London, the University of Gothenburg, the University of Oxford, the Università di Siena, and University College London have been confirmed to lead or moderate various sessions featured during the two-day meeting.

Mike Watson, Chairman of the IPROVE Steering Committee as well as VP Policy at Sanofi Pasteur, commented: “The historical monolithic R&D model is viable for fewer and fewer projects. It is clear that more and more future vaccine R&I successes will rely on effective sharing of expertise and resources. If we can do this more effectively across European centres of excellence, we are confident that the final IPROVE roadmap will provide the clear vision, the organisational and process recommendations and impetus to empower the key stakeholders at EU and national levels to re-energise vaccines research excellence, productivity and efficacy in Europe, keeping us as a true world leader.”

The IPROVE project – which is organised around six key topics – is considered crucial to strengthening Europe’s competitiveness and leading position in vaccine research. This aims to ensure that in the future Europe will continue to maintain its leadership position and capacity to tackle unmet medical needs.

IPROVE analyses the entire vaccine innovation chain, from needs identification and conceptualisation to discovery and development, including interventions necessary to improve education curricula, as well as issues around vaccine perception and awareness by the public and healthcare professionals.

Additional goals include favouring a more structured vaccine innovation agenda, tackling changing medical needs, and supporting strained healthcare systems, with new valuable tools for public health.

A final consultation workshop expected to take place later in April 2015 will discuss R&D needs specific to the field of therapeutic vaccines. The launch of the final IPROVE strategic roadmap will take place at the end of the year. This roadmap is designed to shape strategic decisions regarding priorities for future vaccine investment at EU-level as well as at the level of individual member states.

For more information about the IPROVE consortium, please visit http://www.iprove-eu.eu/ or contact info@iprove-eu.eu

 

Notes to editors:

 Details of IPROVE project

Start date: 01/12/2013

End date: 01/12/2015

Project cost: €623,419.40

EU contribution: €496,367

Coordinator: Vaccines Europe/EFPIA

 

Participants

The IPROVE consortium comprises four renowned organisations in the vaccine field in Europe

Vaccines Europe (VE), a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing all major research-based vaccine global companies as well as SMEs operating in Europe.

The European Vaccine Initiative (EVI), a leading European Product Development Partnership supporting the development of effective, accessible and affordable vaccines against diseases of poverty.

The Sclavo Vaccines Association (SVA), a non-profit association whose main objective is to promote vaccine research targeted towards the discovery and study of advanced immunisation technologies.

EATRIS, a European consortium of 75 academic institutions of excellence in translational research, working together to advance candidates into clinical development

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602167.

 

Post a new comment